دورية أكاديمية
أعرض في EDS

The Inconsistent Assessment of Quality of Life in Patients Treated for Head and Neck Cancer with Anti-EGFR Inhibitors: A Systematic Scoping Review.

التفاصيل البيبلوغرافية
العنوان: The Inconsistent Assessment of Quality of Life in Patients Treated for Head and Neck Cancer with Anti-EGFR Inhibitors: A Systematic Scoping Review.
المؤلفون: Sutton SR; Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.; School of Medicine, University of Nevada, Reno, NV 89557, USA., Taniguchi AN; Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA., Nguyen SA; Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA., Albergotti WG; Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA., Kaczmar JM; Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC 29425, USA., Kejner AE; Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA., Newman JG; Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
المصدر: Cancers [Cancers (Basel)] 2023 Apr 26; Vol. 15 (9). Date of Electronic Publication: 2023 Apr 26.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: In patients receiving treatment for head and neck cancer (HNC), there is a correlation between quality of life (QoL) scores and treatment outcomes. Higher QoL scores have been associated with improved survival. Despite this, the assessment of QoL in clinical trials varies considerably. Three databases (Scopus, PubMed, and Cinahl) were queried for articles published in English between 2006 and 2022. Two reviewers (SRS and ANT) performed study screening, data extraction, and risk of bias assessment. The authors identified 21 articles that met the inclusion criteria. A total of 5961 patients were evaluated. QoL was reported as average scores for specific variables across five different surveys in 12 included articles. Supplemental QoL data were available in 10 included studies. Critical appraisal of studies indicated a high risk of bias due to the inclusion of trials. There is no standard method for reporting QoL data in clinical trials for HNC patients undergoing treatment with anti-EGFR inhibitors. Future clinical trials should standardize their method for assessing and reporting quality-of-life data to increase patient-centered care and refine treatment choices to optimize survival.
References: Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):876-886. (PMID: 34098030)
J Natl Cancer Inst. 2021 Feb 1;113(2):171-181. (PMID: 32407532)
J Clin Oncol. 2006 Mar 1;24(7):1072-8. (PMID: 16505426)
Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):687-699. (PMID: 27727066)
Lancet Oncol. 2015 May;16(5):583-94. (PMID: 25892145)
Clin Cancer Res. 2005 Dec 1;11(23):8418-24. (PMID: 16322304)
Oral Oncol. 2021 Nov;122:105517. (PMID: 34560383)
Cancer. 1996 Jun 1;77(11):2294-301. (PMID: 8635098)
Oral Oncol. 2016 Mar;54:68-74. (PMID: 26776757)
Clin Adv Hematol Oncol. 2008 Oct;6(10):742-50. (PMID: 18997665)
J Dent (Shiraz). 2020 Mar;21(1):31-41. (PMID: 32158782)
Oncologist. 2013;18(4):460-6. (PMID: 23576486)
Oral Oncol. 2018 Sep;84:46-51. (PMID: 30115475)
J Soc Integr Oncol. 2006 Summer;4(3):135-8. (PMID: 19169364)
Curr Oncol. 2010 Jul;17 Suppl 1:S18-30. (PMID: 20680104)
Eur J Cancer. 1995 Dec;31A(13-14):2260-3. (PMID: 8652253)
Nat Commun. 2022 Oct 12;13(1):6026. (PMID: 36224187)
Head Neck. 2009 Jan;31(1):64-76. (PMID: 18972411)
Br J Radiol. 2016 Dec;89(1068):20160105. (PMID: 27734748)
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):4-9. (PMID: 18154212)
Arch Otolaryngol Head Neck Surg. 1996 May;122(5):482-7. (PMID: 8615964)
J Pain Symptom Manage. 2015 Sep;50(3):321-7. (PMID: 25975643)
Qual Life Res. 2016 Sep;25(9):2245-56. (PMID: 27039304)
Lancet. 2019 Jan 5;393(10166):40-50. (PMID: 30449625)
Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22. (PMID: 11597400)
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390)
J Clin Oncol. 2009 Apr 10;27(11):1864-71. (PMID: 19289630)
Oral Oncol. 2015 Sep;51(9):875-9. (PMID: 26163437)
J BUON. 2021 Jan-Feb;26(1):138-144. (PMID: 33721444)
Oncology. 2007;72(3-4):152-9. (PMID: 18160805)
Eur J Cancer. 2000 Sep;36(14):1796-807. (PMID: 10974628)
N Engl J Med. 2008 Sep 11;359(11):1116-27. (PMID: 18784101)
Lancet Oncol. 2011 Apr;12(4):333-43. (PMID: 21377930)
J Clin Oncol. 1999 Mar;17(3):1008-19. (PMID: 10071296)
Psychooncology. 2019 Jul;28(7):1367-1380. (PMID: 30838697)
Ann Oncol. 2014 Sep;25(9):1813-1820. (PMID: 24928832)
Arch Otolaryngol Head Neck Surg. 2001 Jun;127(6):673-8. (PMID: 11405866)
Ann Intern Med. 2018 Oct 2;169(7):467-473. (PMID: 30178033)
Cancer. 2011 Jan 15;117(2):318-26. (PMID: 20830768)
JAMA Oncol. 2019 Dec 1;5(12):1749-1768. (PMID: 31560378)
Oncol Rep. 2009 Apr;21(4):1023-8. (PMID: 19288004)
Target Oncol. 2009 Apr;4(2):107-19. (PMID: 19452131)
Biologics. 2013;7:77-90. (PMID: 23723688)
J Clin Oncol. 1993 Mar;11(3):570-9. (PMID: 8445433)
Ann Oncol. 2019 Nov 1;30(11):1831-1839. (PMID: 31501887)
Value Health. 2021 Feb;24(2):250-267. (PMID: 33518032)
Oncologist. 2010;15(9):994-1001. (PMID: 20798198)
Expert Opin Investig Drugs. 2002 Jun;11(6):755-68. (PMID: 12036420)
Lancet. 2019 Jan 5;393(10166):51-60. (PMID: 30449623)
Head Neck. 1993 Nov-Dec;15(6):485-96. (PMID: 8253555)
Gastroenterology. 2004 Jan;126(1 Suppl 1):S124-8. (PMID: 14978648)
Health Qual Life Outcomes. 2018 Sep 14;16(1):183. (PMID: 30217200)
Head Neck. 2020 May;42(5):828-838. (PMID: 31903657)
Health Qual Life Outcomes. 2020 Jun 22;18(1):195. (PMID: 32571349)
JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):842-9. (PMID: 27389475)
J Clin Oncol. 2008 Jun 1;26(16):2754-60. (PMID: 18509185)
فهرسة مساهمة: Keywords: anti-EGFR inhibitors; head and neck cancer; quality of life
تواريخ الأحداث: Date Created: 20230513 Latest Revision: 20230515
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10177329
DOI: 10.3390/cancers15092475
PMID: 37173942
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15092475